The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 5, Issue 3, 2008, Pages 147-152

  Walker, Paul P ^a,b   Calverley, Peter M A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Clinical Sciences Centre   (United Kingdom)

Author keywords

Bronchodilator response; Chronic obstructive pulmonary disease; Volume response

Indexed keywords

SALBUTAMOL;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; VITAL CAPACITY;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 45949104550     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550802092928     Document Type: Article

References (26)

1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
2. Nisar M, Harris JE, Pearson MG, Calverley PMA. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:555-559.
3. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5:659-664.
4. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542-549.
5. American Thoracic Society/European Respiratory Society 2005. Standards for the diagnosis and treatment of people with COPD. Accessed 24 July 2007. URL: http://www.ersnet.org.
6. Global Initiative for Chronic Lung Disease (GOLD) 2006. GOLD Workshop Report, 2006 update. Accessed 24 July 2007. URL: http://www.gold.com.
7. National Institute for Clinical Effectiveness 2004. Chronic Obstructive Pulmonary Disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Accessed 24 July 2007. URL: http://www.nice.org.uk.
8. Ramsdell JW, Tisi GM. Determination of bronchodilation in the clinical pulmonary function laboratory. Chest 1979; 76:622-662.
9. Girard WM, Light RW. Should the FVC be considered in evaluating response to bronchodilator. Chest 1983; 84:87-89.
10. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, van de Woestijne KP, Brusasco V. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88:1989-1995.
11. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55:289-294.
12. American Thoracic Society. Standardization of Spirometry, 1994 Update. Am J Respir Crit Care Med 1995; 152:1107-1136.
13. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique, 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198.
14. Tweeddale PM, Alexander F, McHardy GJR. Short-term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax 1987; 42:487-490.
15. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25:186-99.
16. Hansen EF, Phanareth K, Laursen LC, KokJensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1267-1271.
17. Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of Primary Care Spirometry on the Diagnosis and Management of COPD. Eur Respir J 2006; 28:945-952.
18. Belman, MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967-975.
19. Pellegrino R, Brusasco V. Lung hyperinflation and flow limitation in chronic airway obstruction. Eur Respir J 1997; 10:543-549.
20. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive disease patients. Eur Respir J 1998; 12:799-804.
21. Boni E, Corda L, Franchini D, Chiroli P, Damiani GP, Pini L, Grassi V, Tantucci C. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57:528-532.
22. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:1510-1516.
23. Hadcroft J, Calverley PMA. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56:713-720.
24. Aliverti A, Rodger K, Dellaca RL, Stevenson N, Lo Mauro A, Pedotti A, Calverley PM. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax 2005; 60:916-924.
25. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664.
26. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:814-819.